Methylxanthine for the prevention and treatment of apnea in preterm infants

To determine the effects of methylxanthine administration on the incidence of apnea and longer-term clinical outcomes in preterm infants including infants at risk for or having apnea and preterm infants peri-extubation.

This is a protocol.

Share/Save